Zum Inhalt springen
Home » Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma

CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysis The post Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma appeared first on Bio Tech Winners.

Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma